Threeby certify that this octrospondence is being filed via BFS. Web with the United States Phont and Trademark Office on September 26, 2006.

TOWNSEND and TOWNSEND and CREW LLP

By: //Ason Hokaserra/

Attorney Docket No.: 082368-007500US Client Reference No.: ONC-A0306P2-US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Confirmation No ·

Yusuke NAKAMURA et al.

Examiner:

Application No.: 10/573,297

Art Unit:

Int'l Application No.: PCT/JP04/14438

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and

Int'l Filing Date: September 24, 2004 For: METHOD OF DIAGNOSING \$1.98

BREAST CANCER

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of references AD-AM are provided. Copies of US Patents and Patent Publications, references AA-AC are not enclosed in compliance with the provisions of 37 CFR §1.98(a)(2). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Yusuke NAKAMURA et al. Application No.: 10/537,297 Page 2

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overnavment to the above-noted Denosit Account.

Respectfully submitted,

/Kevin Bastian/

Kevin Bastian Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834 Tel: 415-576-0200 Fax: 415-576-0300 KLB:3th

Substitute for form 14494	14494/PTD			Complete if Known		
			Application Number	10/573,297		
INFORMATION	ON DISCLO	SURE	Filing Date	September 24, 2004		
STATEMENT BY APPLICANT		First Named Inventor Nakamura, Yus	Nakamura, Yusuke			
			Art Unit			
(Use as many	sheets as necessar	yl	Examiner Name			
Sheet 1	of.	2	Attorney Docket Number	082368-007500US		

U.S. PATENT DOCUMENTS					
Examiner Indula*	Cite No 1	Document Number	Publication Date MB-QQ-YYYY	Name of Patertice or Applicant of Cated Document	Pages Columns, Lines, Where Relevant Passages or Relevant
	1.00	Number Kind Code <sup>2 (Flores)</sup>		- Appendix of Contraction	Figures Appear
	AA	6,365,358 B1	04-02-2002	Hillman et al.	
	AB.	2003/0157544 A1	08-21-2003	Gish et al.	
	AC	2003/0104418 A1	08-05-2003	Zhang et al.	

## FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, Examiner Foreign Patent Document Publication Date Name of Patentee or Where Relevant Passages or Relevant Figures Appear Indials\* MM-DD-YYYY Applicant of Cried Document Number<sup>4</sup> Kind Code<sup>5</sup> (if kno AD WO 02/04514 A2 01-17-2002 Conxa Corporation

Examiner Signature	Date Considered	

EXAMERS final if reference considents, whether or not define in a collection of a MEEP 500. Date in through claffor if it is continuous and in the collection of the collectio

Substitute for form 1449B/PTO		Complete if Known				
				Application Number	10/573,297	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			SURE	Filing Date	September 24, 2004	
			CANT	First Named Inventor	Nakamura, Yusuke	
				Art Unit		
	(Use as many sheets as necessary)			Examiner Name		
Sheet	2	ot	2	Altorney Docket Number	082368-007500US	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	include name of the author (in CAPITAL LETTERS), tills of the article (when appropriate), till of the fem (book, magazine, journal, serial, symposium, catalog, etc.), disk, page(s), volume-issue number(s), publisher, city and/or country where published.	Т:			
	AE	ADAM, Paul J. et al.; "Anylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro"; <u>Molecular Cancer</u> <u>Research</u> 1:826-835 (September 2003)				
	AF	DRESSMAN, Markene A. et al.; "Gene expression in profiling detects gene amplification and differentiates tumor types in breast cancer"; <u>Cancer Research</u> 63:2194-2199 (May 1, 2003)				
	AG	GEYLAN, Y.S. et al.; "Anylamine N-acetyltransferase activities in human breast cancer tissues"; Necolasma 48(2):108-111 (2001)				
	АН	LIPKOWITZ, Stan; "The role of ubiquitination-proteasome pathway in breast cancer: Ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer": <u>Breast Cancer Research 5(1)</u> 8-15 (2003)	С			
	AI	ORLOWSKI, Robert Z, and E. Claire Dees; "The role of ubiquitination-proteasome pathway in breast cancer." Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer." <u>Breast Cancer Research</u> 5(1):1-7 (2003)				
	AJ	PEROU, Charles M. et al.; "Molecular portraits of human breast tumors"; Nature 406:747-752 (August 17, 2000)				
	AK	SGROI, Dennis C. et al.; "In vivo gene expression profile analysis of human breast cancer progression"; <u>Cancer Research</u> 59:5656-5661 (November 15, 1999)				
	AL	DATABASE; EBI Accession No. AX369194; "Sequence from patent WO0204514"; February 15, 2002	⊏			
	AM	DATABASE EBI Accession No. AAM56211; "Sequence 1 from patent US 6365358" June 20, 2002				

Examiner Signature	Date Consider	ed .

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant.

\*\*Applicant's unique citation designation number (optional)\*\*, "Applicant's into place a check mark here if English language Translation is attached.